On March 15, 2021 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, reported that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021 (Press release, Cue Biopharma, MAR 15, 2021, https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-present-corporate-overview-and-clinical-progress [SID1234608283]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cue Biopharma will provide a corporate update highlighting clinical progress with CUE-101, the lead Immuno-STAT (Selective Targeting and Alteration of T cells) platform-based therapeutic, in clinical trials for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The presentation will also focus on the Company’s platform developments and pipeline progress including the CUE-400 series, a novel class of therapeutic molecules for broad applications in multiple autoimmune diseases.

Presentation Details

Oppenheimer 31st Annual Healthcare Conference
Date and Time: Thursday, March 18, 2021 at 9:20 a.m. EDT
Webcast link: View Source
A live and archived webcast of the presentation will be available in the Investors and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.